Clinical trials: Immune System Disorder (Healthy Volunteer)
Juvenile Idiopathic Arthritis
Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers
This is an assessment of Pharmacokinetics of a single oral dose of VIMOVO in healthy adult volunteers.
- Trial name
- NCT01358383
- Testing
- naproxen, esomeprazole
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV, AIDS
TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.
The purpose of this study is to investigate the pharmacokinetic interaction between the combination of ethinylestradiol and norethindrone and TMC278 25 mg once daily.
- Conditions
- HIV, AIDS, Oral Contraceptive
- Trial name
- NCT00739622
- Testing
- TMC278
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Asthma
Bioequivalence Study of Montelukast 10 mg Tablets
The objective of this study was to confirm if two formulations of montelukast tablets are bioequivalent. Test product was Montelukast (10 mg tablets; GlaxoSmithKline) and reference product Singulair (10 mg tablets; Merck Sharp \&…
- Trial name
- NCT01943942
- Testing
- Montelukast 10 mg
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection
This study will determine the safety and side effects of two experimental HIV vaccines given in a "prime-boost" schedule. It will also monitor participants for the social impact of being in an HIV vaccine study (e.g., problems…
- Trial name
- NCT00109629
- Testing
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Colitis, Ulcerative
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants
This is a first time in human study designed to assess the safety, tolerability, pharmacokinetics and PD of GSK3888130B over a range of dose levels in healthy participants.
- Trial name
- NCT05131971
- Testing
- GSK3888130B
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers
Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid…
- Trial name
- NCT00279734
- Testing
- Tetanus + pnemococcal vaccines alone, Abatacept + vaccines
- Where
- 3 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infection, Healthy
The Effect of Milk Thistle on the Pharmacokinetics of Indinavir
Complementary and alternative medicines are widely used in the HIV-infected population. Recent data have shown serious drug interactions between certain complementary medicines and protease inhibitors.
- Trial name
- NCT00011635
- Testing
- Silymarin (milk thistle)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Infection, Human Immunodeficiency Virus
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
LAI115428 is a Phase I, randomized, repeat dose escalation study to determine the safety, tolerability, and PK profile of intramuscular and subcutaneous injections of GSK1265744 in a long acting parenteral (LAP) formulation in…
- Trial name
- NCT01593046
- Testing
- GSK1265744 Oral, GSK1265744 LAP 800mg intramuscular injection, GSK1265744 LAP 200mg subcutaneous injection
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Chronic Spontaneous Urticaria
A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers.
- Trial name
- NCT06294288
- Testing
- LP-003 Dose 1 (Single), LP-003 Dose 2 (Single), LP-003 Dose 3 (Single)
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Longbio Pharma
Multiple Sclerosis, Acute Optic Neuritis
Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
The primary objective of the study is to characterize the pharmacokinetics (PK) of BIIB033-B and to compare the PK profile with that of BIIB033-A in healthy volunteers.
- Trial name
- NCT02833142
- Testing
- BIIB033 (opicinumab)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Biogen
Atopic Dermatitis
Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis
Part 1: To investigate the safety and tolerability of intravenous (IV) or subcutaneous (SC) administration of a single dose of KHK4323 to Japanese or Caucasian healthy adult males in a double-blind, placebo-controlled study.
- Trial name
- NCT03846466
- Testing
- KHK4323 IV/S, KHK4323 SC/S, KHK4323 IV/M
- Where
- Japan
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
HIV Infections, HSV-2 Genital Herpes
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013…
- Trial name
- NCT00740584
- Testing
- 3% SPL7013 Gel (VivaGel)
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Starpharma Pty Ltd
HIV Infections
Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers
This study will test the safety of a HIV DNA vaccine after it is injected into your muscle using an electroporation device (TriGrid™ Delivery System made by Ichor Medical Systems), and will test the ability of the vaccine to help…
- Trial name
- ADVAX-EP (NCT00545987)
- Testing
- TriGrid™ Delivery System, conventional intramuscular injection
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Rheumatoid Arthritis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects and intravenous doses in rheumatoid…
- Trial name
- NCT02089087
- Testing
- CFZ533
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
HIV Infection
Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults
The purpose of this study is to determine the safety and immune response to a investigational DNA Plasmid HIV vaccine, ADVAX e/g + ADVAX p/n-t (ADVAX), at three different dosage levels, in adults who are not infected with HIV.
- Trial name
- C001 (NCT00249106)
- Testing
- ADVAX
- Where
- 2 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Hepatitis B
Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.
The current study will evaluate immunological memory to hepatitis B antigen in subjects who received primary neonatal vaccination of hepatitis B vaccine (Engerix™-B ), 20 years ago in the primary study and who have anti-HBs…
- Trial name
- NCT00456625
- Testing
- Engerix™-B
- Where
- Thailand
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278
The purpose of this study is to examine the safety, local tolerability and pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of a…
- Trial name
- NCT01031589
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Atopic Dermatitis
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.
- Trial name
- NCT06268860
- Testing
- Rocatinlimab vial injection, Rocatinlimab prefilled syringe
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Amgen
HIV Infections
A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants
This is a 3 part study of an investigational capsid inhibitor, VH4004280, in healthy adult participants. The purpose is to evaluate the effect of tablet formulation as well as food on bioavailability.
- Trial name
- NCT06168318
- Testing
- VH4004280 Formulation A, VH4004280 Formulation B, VH4004280 Formulation C
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
IgA Nephropathy
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).
- Trial name
- NCT03945318
- Testing
- BION-1301 Single Dose, BION-1301 Multiple Doses
- Where
- 16 sites in United States, South Korea and 1 more
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.